Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial.
作者信息
Marmorino Federica, Falcone Alfredo, Cremolini Chiara
机构信息
Chiara Cremolini: Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
出版信息
Oncotarget. 2019 Apr 19;10(29):2791-2792. doi: 10.18632/oncotarget.26870.
Abstract
摘要
相似文献
1
Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial.贝伐单抗作为转移性结直肠癌的维持治疗：解读MOMA试验结果。
Oncotarget. 2019 Apr 19;10(29):2791-2792. doi: 10.18632/oncotarget.26870.
2
The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902).CapeOX联合贝伐单抗治疗后序贯卡培他滨联合贝伐单抗维持治疗转移性结直肠癌患者的疗效与安全性：一项多中心、单臂、II期研究（CCOG-0902）
BMC Cancer. 2017 Apr 4;17(1):243. doi: 10.1186/s12885-017-3245-1.
3
Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.转移性结直肠癌（mCRC）中抗血管生成治疗的生物标志物：原始数据及文献综述
Z Gastroenterol. 2011 Oct;49(10):1398-406. doi: 10.1055/s-0031-1281752. Epub 2011 Sep 30.
4
A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer.一项关于阿昔替尼单药作为转移性结直肠癌患者一线接受改良FOLFOX/贝伐单抗治疗后维持治疗的2期试验。
Cancer Invest. 2017 Jul 3;35(6):386-392. doi: 10.1080/07357907.2017.1310221. Epub 2017 Apr 20.
5
Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.贝伐单抗联合厄洛替尼作为转移性结直肠癌患者维持治疗的生存获益与安全性：一项荟萃分析
Clin Drug Investig. 2017 Feb;37(2):155-165. doi: 10.1007/s40261-016-0465-0.
6
Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.获得生物制剂与生存率提高的关联：南澳大利亚州（SA）转移性结直肠癌（mCRC）登记处的结果。
Acta Oncol. 2016;55(4):480-5. doi: 10.3109/0284186X.2015.1117135. Epub 2016 Feb 15.
7
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.贝伐珠单抗联合或不联合厄洛替尼作为转移性结直肠癌（GERCOR DREAM；OPTIMOX3）患者的维持治疗：一项随机、开放标签、3 期临床试验。
Lancet Oncol. 2015 Nov;16(15):1493-1505. doi: 10.1016/S1470-2045(15)00216-8. Epub 2015 Oct 22.
8
A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.一项针对经大量前期治疗的转移性结直肠癌患者的单臂II期试验，采用S-1、口服亚叶酸钙和贝伐单抗联合化疗。
BMC Cancer. 2015 Aug 27;15:601. doi: 10.1186/s12885-015-1606-1.
9
The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.在转移性结直肠癌患者一线治疗中添加贝伐单抗的“现实生活”影响：一项大型以色列回顾性队列研究。
Acta Oncol. 2015 Feb;54(2):164-70. doi: 10.3109/0284186X.2014.958532. Epub 2014 Oct 28.
10
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.FOLFIRI/Flox 三联化疗联合贝伐珠单抗治疗转移性结直肠癌患者的肝转移切除术的疗效。
Clin Colorectal Cancer. 2012 Jun;11(2):119-26. doi: 10.1016/j.clcc.2011.11.002. Epub 2011 Dec 27.
本文引用的文献
1
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.贝伐珠单抗或贝伐珠单抗联合节拍化疗作为转移性结直肠癌一线诱导治疗后维持治疗的 II 期随机研究：MOMA 试验
Eur J Cancer. 2019 Mar;109:175-182. doi: 10.1016/j.ejca.2018.12.028. Epub 2019 Feb 5.
2
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.卡培他滨节拍化疗治疗难治性转移性结直肠癌患者的药代动力学分析。
Invest New Drugs. 2018 Aug;36(4):709-714. doi: 10.1007/s10637-018-0579-8. Epub 2018 Feb 27.
3
Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).贝伐珠单抗维持治疗与转移性结直肠癌化疗间歇期无维持治疗的比较：一项随机 III 期试验（PRODIGE 9）。
J Clin Oncol. 2018 Mar 1;36(7):674-681. doi: 10.1200/JCO.2017.75.2931. Epub 2018 Jan 18.
4
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.ESMO 共识指南：转移性结直肠癌患者的管理。
Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.
5
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.一线奥沙利铂联合氟尿嘧啶类加贝伐珠单抗治疗转移性结直肠癌患者后的维持策略（AIO 0207）：一项随机、非劣效性、开放标签、III 期临床试验。
Lancet Oncol. 2015 Oct;16(13):1355-69. doi: 10.1016/S1470-2045(15)00042-X. Epub 2015 Sep 8.
6
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.转移性结直肠癌的 FOLFOXIRI 和贝伐珠单抗初始治疗。
N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108.
7
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.UFT 节拍化疗联合塞来昔布与环磷酰胺治疗晚期难治性胃肠道肿瘤的临床、药代动力学和药效学评价。
Angiogenesis. 2012 Jun;15(2):275-86. doi: 10.1007/s10456-012-9260-6. Epub 2012 Mar 2.
8
The anti-angiogenic basis of metronomic chemotherapy.节拍化疗的抗血管生成基础。
Nat Rev Cancer. 2004 Jun;4(6):423-36. doi: 10.1038/nrc1369.
Zotero 插件